

Development of a stent for the treatment of lower extremity artery disease, aimed at conducting clinical trials in Japan and obtaining regulatory approval in the U.S. (Global Vascular Co., Ltd.)



City	Year of Establishment	Founder
Chiyoda-ku, Tokyo	2022	Kenta Bito Shunto Maegawa

Partner VC	Latest round of Fundraising	Valuation
Diamond Medino Capital Co., Ltd.	Series B	Non-Disclosure

Contact Information :Please fill out the inquiry form on the company website and submit to us

Website : <https://www.g-vasc.com/>

○ Business Plan

Lower Extremity Artery Disease (LEAD), an ischemic disease that affects the arteries in the lower limbs, is estimated to have a potential patient population of more than 200 million worldwide. In particular, the below-the-knee(BTK) vascular region remains challenging for achieving long-term patency treatment because narrow vessel diameters and slow blood flow increase the risk of restenosis. Through the development of the BioStealth™ drug-eluting stent*, we aim to create a future in which LEAD patients—especially those who have long faced limited treatment options—can receive therapy with confidence and benefit from sustained treatment outcomes.

*BioStealth™ is a concept for a stent that we are currently developing.

○ Research Outline

There are currently no stents available for peripheral artery disease in the below-the-knee region, where the foreign body reaction between living tissue and artificial objects is most severe. We are developing a drug-eluting and self-expandable stent that is highly biocompatible and capable of long-term patency even in the below-the-knee region by utilizing our unique biomaterial and drug-eluting coating techniques along with an ultra-thin stent design that is resistant to deformation.

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	PCA 2025~2027FY	Non-Disclosure	United States

○ International collaborative technology demonstration

-Relationship development with potential local partner

In order to achieve a timely IDE submission in the U.S., we will collaborate with U.S.-based testing laboratories to collect supplemental data that address the gaps between U.S. requirements and the clinical trial notification (CTN) submitted in Japan.